MIRA
INFORM REPORT
|
Report Date : |
16.07.2008 |
IDENTIFICATION
DETAILS
|
Name : |
DELTA PHARMA |
|
|
|
|
Registered Office : |
36 Makkram Ebeid Street,
Nasr City, Cairo |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Financials (as on) : |
31.12.2007 |
|
|
|
|
Date of Incorporation : |
May 1997 |
|
|
|
|
Com. Reg. No.: |
2930348, Cairo |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture of Therapeutic
and Diagnostic Blood Derivatives, Plasma Substitutes and Medical Laboratories
Requisites, as well as
Pharmaceuticals |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 250,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : DELTA PHARMA
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : May 1997
Commercial Registration Number : 2930348, Cairo
Issued Capital : £E 800,000
Paid up Capital : £E 800,000
Total Workforce : 100
Activities :
Manufacture of therapeutic and
diagnostic blood derivatives, plasma
substitutes and medical laboratories requisites, as well as pharmaceuticals
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
Recommended Credit Limit : US$ 250,000
COMPANY NAME
DELTA PHARMA
ADDRESS
Registered & Physical Address
Street : 36 Makkram Ebeid Street
Area : Nasr City
Town : Cairo
Country : Egypt
Telephone : (20-2) 22877791
/ 22877792 / 22877793
Facsimile : (20-2) 22877794
Mobile : (20-)
Email : info@deltapharmaegypt.com
Premises
Subject operates
from a medium sized suite of offices that are rented and located in the Central
Business Area of Cairo.
Branch Office (s)
Location Description
·
Public Free
Zone, Block F Factory
premises
Nasr City
Cairo
Tel: (20-2) 2740163 / 2746425
Fax: (20-2) 4021784
KEY PRINCIPALS
Name Position
·
Dr
Mohy Mohamed Hafiz Chairman
·
Dr. Mohamed Tawfik El Rakhawy Director
·
Dr. Raouf Hakim Elias Director
·
Bassel Raouf Hakim Director
·
Dr. Fayez Shafik General
Manager
·
Dr Mohamed
Abbas Commercial
Manager
·
Hajaj
Hussain Human
Resources Manager
LEGAL FORM & OWNERS
Date of Establishment : May 1997
Legal Form :
Egyptian Joint Stock
Company
Commercial Reg. No. : 2930348, Cairo
Issued Capital : £E 800,000
Paid up Capital : £E 800,000
Name of Shareholder (s)
·
Dr
Mohy Mohamed Hafiz
·
Dr. Mohamed Tawfik El Rakhawy
·
Dr. Raouf Hakim Elias
·
Bassel Raouf Hakim
OPERATIONS
Activities: Engaged in the manufacture of therapeutic and
diagnostic blood derivatives, plasma substitutes and
medical
laboratories requisites, as well as pharmaceuticals.
Import
Countries: Germany, Japan
and India
Operating Trend: Steady
Subject has a
workforce of 100 employees.
FINANCIAL DATA
Financial
highlights provided by local sources are given below:
Currency: Egyptian
Pounds (£E)
Year
Ending 31/12/06: Year
Ending 31/12/07:
Total Sales £E 24,250,000 £E 27,100,000
Local sources
consider subject’s financial condition to be Fair.
The above financial
figures are based on estimations by our local sources.
BANKERS
·
National Bank
of Egypt
24, Sherif Street
Cairo
Tel : (20-2) 3924175
Fax : (20-2) 3924143
·
Cairo Far East
Bank SAE
PO Box : 757
Cairo
Tel : (20-2) 3713554 / 3710280
Fax : (20-2) 3483818
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
Date of
transaction December
2004
Credit amount 100,000
Amount overdue 0
Payment terms 60
days
Payment Method Letters
of Credit
Paying record No
Complaints
Currency US
Dollars
GENERAL COMMENTS
Delta Pharma was
established in 1997 and is engaged in the manufacture of therapeutic and diagnostic
blood derivatives, plasma substitutes and medical laboratories requisites, as
well as pharmaceuticals.
During the course
of this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.43.17 |
|
UK Pound |
1 |
Rs.86.46 |
|
Euro |
1 |
Rs.68.68 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)